Yogesh Reddy
@yreddyhf
HF doc at Mayo Clinic, interested in HFpEF, PAH, valve hemodynamics
ID:759109431061729280
29-07-2016 19:32:47
749 Tweets
1,0K Followers
275 Following
Follow People
James Januzzi Jr MD
Adolph Hutter Professor at Harvard and @MGHHeartHealth. Chief Scientific Officer @BaimInstitute. @RedSox team doc. Deputy Editor @JACCJournals.
Andrew J Sauer MD
Cardiologist @MidAmericaHeart, building programs to implement therapies, advance discovery, and foster innovation for patients suffering from heart failure.
JACC Journals
Official account representing the ACC's #JACCJournals, one of the most widely read & most impactful CV journal programs in the world. @ACCinTouch #JACC
Ryan J Tedford MD
Chief, Heart Failure; Med Director, Cardiac Transplant; Prof of Medicine & P. Gazes Chair @MUSChealth; Father and Husband; RV Centric Views and Hemodynamicist
Michelle Kittleson MD PhD
#kittlesonrules | Cardiologist | Prof of Medicine @CedarsSinai | Author Mastering the Art of Patient Care available at https://t.co/zdJT2MVNhb
Roger Borràs Elmir Omerovic Judea Pearl Adan Z Becerra, PhD Gregg W. Stone MD Xuanyu Shi Giulio Grossi Sanjay Kaul Stephen John Senn John Mandrola, MD Vinay Prasad MD MPH RWE is a truly bullshit term. The real world simply does not provide evidence about what would have happened to a patient had they received a different treatment from the one they received, except in cases (that are almost nonexistent) where treatment choices are dictated.
#MiltonPacker at our session on evidence generation in acute #HF
#Estimates of Tx efficacy early in trial f/u period: NOT reliable (overestimate size of Tx effect, based on a few early events)
I highlight this point in Methods classes, so being selective in my post🙂 #CVCT2023
#aorticstenosis : The valve vs. #HFpEF !
Read the latest paper from our group European Society of Cardiology Journals :
academic.oup.com/ehjcimaging/ar…
Exercise impairment & adverse hemodynamics correspond better w HFpEF phenotype than AS severity...
Sarah Hoedemakers Jan Verwerft Yogesh Reddy Guido Claessen Cosyns Bernard
First study that identifies a novel, genetic mediator for improvement in LVEF in DCM that modulates cardiac fibrosis. Could be an important target to improve LVEF and fibrosis. So proud of my lab and Duan Liu. Grateful to Mayo Clinic Center for Individualized Medicine Mayo Clinic CV and my worldwide collaborators
Withdrawal of #GDMT in HF consistently ➡️adverse clinical course⚠️
#ACEi in HFrEF ( #QuinaprilHeartStudy ) sciencedirect.com/science/articl…
#SGLT2i in HF ( #EMPEROR )
ahajournals.org/doi/10.1161/CI…
#MRA in HFmrEF/HFpEF (tested in #FINEARTS )
#GDMT in HFimpEF DCM ( #TREDHF )
thelancet.com/article/S0140-…
Impressive findings
Kalyanam Shivkumar MD PhD Ali Nsair, MD
Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation | NEJM nejm.org/doi/full/10.10…
🔥 BREAKING 🔥
Mikhail Kosiborod from Saint Luke's Mid America Heart Institute
❇️STEP-HFpEF, semaglutide
Obesity-phenotype HFpEF
🔆 Dual primary endpt. achieved
1. 🔼 health status (KCCQ)
2. 🔽 weight
3. 🚶 🔼 walk distance
4. Reduced NTproBNP
The beginning of a new era of therapies for this…
#SGLT2i 's benefit in #HFpEF , but why and how?
First in HFpEF! SGLT2i's effect on #PCWP by #RHC in a mechanistic randomized trial. #Dapa ⬇️PCWP, improving the fundamental hemodynamic abnormality underlying HFpEF. Circulation Mayo Clinic Yogesh Reddy #Borlaugslab ahajournals.org/doi/10.1161/CI…
Exploring the phenotypes of #HFpEF may help better identify HFpEF risk profile and may be more amenable specific treatment? We found that 10–25% with HFpEF without #lung disease develop arterial #hypoxemia during #exercise .
Mayo Clinic Research Unit of Cardiology, OUH Yogesh Reddy Borlaug
1/2
